Table 3. Factors associated with malignancy of thyroid nodule with architectural before and after reclassification.
| Present classification | P-value | After reclassification | P-value | ||||
|---|---|---|---|---|---|---|---|
| Benign | Malignant | Benign | NIFTPs | Malignant | |||
| No. of nodules | 225 (59) | 159 (41) | 225 (59) | 39 (10) | 120 (31) | ||
| Size (cm) | 2.4 (1.7–3.4) | 2.5 (1.7–3.6) | 0.527* | 2.4 (1.7–3.4) | 2.3 (1.4–3.1) | 2.7 (1.8–3.6) | 0.089‡ |
| CNB diagnoses | 0.006† | 0.003§ | |||||
| AUS-A | 131 (58) | 69 (43) | 131 (58) | 19 (49) | 50 (42) | ||
| FN/SFN | 94 (42) | 90 (57) | 94 (42) | 20 (51) | 70 (58) | ||
| Presence of malignant US features | <0.001† | <0.001§ | |||||
| Yes | 81 (36) | 85 (53) | 81 (36) | 20 (51) | 65 (54) | ||
| Nuclear atypia | <0.001† | <0.001§ | |||||
| yes | 8 (4) | 36 (23) | 8 (4) | 15 (38) | 21 (18) | ||
NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features. CNB, core needle biopsy; AUS-A, atypia of undetermined significant with architectural atypia; FN/SFN, follicular neoplasm/suspicious for a follicular neoplasm;US, ultrasonography. Variables were presented as number with percentages.
*P value was estimated by Wilcoxon signed-rank test.
†P value was estimated by Chi-square test.
‡P value was estimated by Kruskal-Wallis test.
§P value was estimated by Cochran-Armitage trend test.